Phillip Securities lifts C&O Pharmaceutical (E92.SG) target price to $0.65 from $0.53, implying 13.7x FY11 P/E, after increasing FY11 earnings estimate by 8.6% to HK$175 million ($30.5 million) to assume stronger growth across all business segments, contributions from roll-out of new drugs, keeping Buy call, according to Dow Jones.
Phillip expects new drug Edaravone, used to aid neurological recovery, to be major earnings driver in coming years considering fewer than five manufacturers in China capable of producing it.
Broker notes market for this drug, which C&O expects to get regulatory approval for mass production by October, worth about RMB1 billion ($200 million) in 2009. Shares flat at $0.465.
Monday, August 30, 2010
C&O Pharma target raised to $0.65 by Phillip Securities
As reported at
Subscribe to:
Post Comments (Atom)
-
Installed FortiClient recently but the challenge in disabling the application/service from running automatically on every start-up annoyed m...
-
The Belt and Road Initiative is envisioned to enhance connectivity across continents through infrastructure investment, cultural exchange a...
-
To coincide with the current movie screening of Disney's Dumbo, I present you the main song for Dumbo. Enjoy! Lyrics Baby mine, do...
-
If you have never heard of the case of Cambridge Analytica with Facebook, then you must be living in some cave. Ever since the scandal was...
No comments:
Post a Comment
Do provide your constructive comment. I appreciate that.